Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07436676

Safety and Feasibility Evaluation of ALVIV Laser Based Treatment for Fecal Incontinence

Led by Alviv Ltd. · Updated on 2026-02-27

12

Participants Needed

1

Research Sites

99 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose if this interventional First in Human study is to assess the Safety and Performance of the ALVIV System laser based treatment in patients diagnosed with Fecal Incontinence. Eligible patients will go through screening assessments, followed by a series of 4-6 treatments with 3 weeks apart. Last follow up visit to the study will occur 3 weeks after last treatment day. Participants will be asked to maintain a diary of their fecal incontinence episodes, and complete quality of life and satisfaction questionnaires throughout the study.

CONDITIONS

Official Title

Safety and Feasibility Evaluation of ALVIV Laser Based Treatment for Fecal Incontinence

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Onset of symptoms for uncontrolled passage of fecal material for at least 6 months prior to enrollment.
  • At least 2-4 staining, solid or liquid fecal incontinence episodes in the 4 weeks prior to enrollment
  • Documented normal colonoscopy in the last 3 years
  • Normal sigmoidoscopy as part of screening
  • Signed consent
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding women
  • Rectal prolapse grade 65 III
  • Hemorrhoids Grade 65 II
  • Obstetrical injuries including third- and fourth-degree tears in the anal sphincter within the past 6 months
  • Internal anal sphincter separation greater than 270 degrees on Transrectal Ultrasound (TRUS)
  • Congenital malformation of anus or rectum
  • History of pelvic surgery in the past 6 months
  • Inflammatory bowel disease
  • Presence of intestinal stoma
  • History of pelvic radiation within the previous 12 months or presence of active radiation proctitis
  • Presence of existing implant in the anal or rectal region
  • Active anal or rectal conditions in the last 6 months
  • Abnormal blood coagulation
  • Patients currently receiving immunotherapy or chemotherapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Meir Medical Center

Kfar Saba, Israel, 4428164

Actively Recruiting

Loading map...

Research Team

S

Shira Doron

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here